Apixaban and Cardiotoxicity - a phase IV clinical study of FDA data

Summary:

Cardiotoxicity is reported as a side effect among people who take Apixaban (apixaban), especially for people who are male, 50-59 old, also take Synthroid, and have Atrial fibrillation/flutter.

The phase IV clinical study analyzes which people have Cardiotoxicity when taking Apixaban. It is created by eHealthMe based on reports of 60,044 people who have side effects when taking Apixaban from the FDA, and is updated regularly.

What is Apixaban?

Apixaban has active ingredients of apixaban. It is often used in blood clots. eHealthMe is studying from 60,351 Apixaban users. Check the latest studies of Apixaban.

What is Cardiotoxicity?

Cardiotoxicity (damage to the heart muscle) is found to be associated with 384 drugs and 511 conditions by eHealthMe. Check the latest studies of Cardiotoxicity.

On Aug, 04, 2026

60,044 people reported to have side effects when taking Apixaban.
Among them, 14 people (0.02%) have Cardiotoxicity.

Among these 14 people:

What is the gender of people who have Cardiotoxicity when taking Apixaban? *

female: 38.46 %
male: 61.54 %

What is the age of people who have Cardiotoxicity when taking Apixaban? *

What are other drugs people take besides Apixaban? *

What are other side effects people have besides Cardiotoxicity? *

Cardiogenic Shock (inadequate circulation of blood): 9 people, 64.29%
Overdose: 6 people, 42.86%
Drug Ineffective: 4 people, 28.57%
Bradycardia (abnormally slow heart action): 3 people, 21.43%
Pneumonia: 2 people, 14.29%
Arrhythmias (irregular heartbeat): 2 people, 14.29%
Electrocardiogram Pr Prolongation: 2 people, 14.29%
Hypokalemia (low potassium): 2 people, 14.29%
Septic Shock (shock due to blood infection): 2 people, 14.29%
Cardiac Arrest: 2 people, 14.29%

What are the existing conditions these people have? *

Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 4 people, 28.57%
Cardiogenic Shock (inadequate circulation of blood): 3 people, 21.43%
Overdose: 2 people, 14.29%
Thrombocytopenia (decrease of platelets in blood): 1 person, 7.14%
Rhinorrhea (watery mucus discharge from the nose): 1 person, 7.14%
Renal Cancer Stage Iv (the tumour has spread to areas beyond gerota's fascia and extends into the adrenal gland on the same side of the body as the tumour, possibly to lymph nodes, but not to other parts of the body): 1 person, 7.14%
Nasal Congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels): 1 person, 7.14%
Multiple Myeloma (cancer of the plasma cells): 1 person, 7.14%
High Blood Pressure: 1 person, 7.14%
Headache (pain in head): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Apixaban and have Cardiotoxicity?

- Check whether Cardiotoxicity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Apixaban:

Apixaban (60,351 reports)

Cardiotoxicity treatments and more:

Cardiotoxicity (8,120 reports)

Browse all side effects of Apixaban:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Cardiotoxicity:

Cardiotoxicity (384 drugs)

Browse all the conditions that are associated with Cardiotoxicity:

Cardiotoxicity (511 conditions)

Related publications that referenced our studies

Alam, S., Illo, C., Ma, Y. T., & Punia, P. , "Gemcitabine-induced cardiotoxicity in patients receiving adjuvant chemotherapy for pancreatic cancer: a case series", Case reports in oncology, 2018 Jan .
Alam, S., Illo, C., Ma, Y. T., & Punia, P. , "Gemcitabine-induced cardiotoxicity in patients receiving adjuvant chemotherapy for pancreatic cancer: a case series", Case reports in oncology, 2018 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on apixaban (the active ingredients of Apixaban) and Apixaban (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.